Influence of CYP2D6 Polymorphisms on Serum Levels of Tamoxifen Metabolites in Spanish Women with Breast Cancer
Open Access
- 1 January 2013
- journal article
- Published by Ivyspring International Publisher in International Journal of Medical Sciences
- Vol. 10 (7) , 932-937
Abstract
Background Estrogen receptor-positive breast cancer tumors depend on estrogen signaling for their growth and replication and can be treated by anti-estrogen therapy with tamoxifen. Polymorphisms of the CYP2D6 and CYP2C19 genes are associated with an impaired response to tamoxifen. The study objective was to investigate the impact of genetic polymorphisms in CYP2D6 and CYP2C19 on the pharmacokinetics of tamoxifen and its metabolites in Spanish women with estrogen receptor-positive breast cancer who were candidates for tamoxifen therapy.Keywords
This publication has 34 references indexed in Scilit:
- CYP2D6 Genotype as a Marker for Benefit of Adjuvant Tamoxifen in Postmenopausal Women: Lessons LearnedJNCI: Journal of the National Cancer Institute, 2012
- CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer PatientsJNCI: Journal of the National Cancer Institute, 2012
- CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 TrialJNCI: Journal of the National Cancer Institute, 2012
- Pilot study for the characterization of pharmacogenetically relevant CYP2D6, CYP2C19 and ABCB1 gene polymorphisms in the Hungarian populationCell Biochemistry and Function, 2011
- Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patientsBritish Journal of Clinical Pharmacology, 2011
- CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifenBreast Cancer Research, 2010
- The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancerBritish Journal of Cancer, 2010
- Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention TrialThe Pharmacogenomics Journal, 2010
- Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatmentBreast Cancer Research and Treatment, 2009
- CYP2D6 polymorphism screening in a selected population of Spain (La Alpujarra): No effect of geographical isolationAnnals of Human Biology, 2009